Piramal Pharma Ltd (PPLPHARMA) — shareholding pattern, promoter holding, financials and share price

Piramal Pharma Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as PPLPHARMA and on the BSE under scrip code 543635. Its ISIN is INE0DK501011.

Piramal Pharma Limited (PPL) is part of the Piramal group of companies. The company operates through 3 major segments (1) Contract development and manufacturing organisations (CDMO), (2) Complex hospital generics (critical care), and (3) consumer healthcare (OTC). Company entered Pharma space back in 1988 with acquisition of Nicholas Laboratories and grew through a series of Mergers & Acquisitions [1] and various organic initiatives. In 2010 the Domestic formulations business was sold to Abott for $3.7 billion [2] and Diagnostic Services was sold to Super Religare Laboratories (SRL) [3]

Piramal Pharma Limited is a global pharmaceutical company operating three principal verticals—an integrated CDMO (Piramal Pharma Solutions), Complex Hospital Generics (Piramal Critical Care), and India Consumer Healthcare—providing end-to-end manufacturing across 17 facilities and selling across 100+ countries through differentiated capabilities in HP APIs, ADCs, sterile injectables, biologics, and ICH OTC brands.

Q3 FY'26 and nine-month results show muted revenue performance with reported revenues of approximately Rs. 2,140 crores for the quarter and Rs. 6,117 crores for nine months, a year-on-year decline, while EBITDA margins were resilient at ~11% for the quarter and ~10% for nine months due to cost optimisation and operational excellence.

Listed peers in Pharmaceuticals: Sai Life Sciences Ltd, Neuland Laboratories Ltd, Rubicon Research Ltd, Granules India Ltd, Pfizer Ltd, Astrazeneca Pharma India Ltd.